These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 28736719)

  • 1. Lipid profile in adult patients with Fabry disease - Ten-year follow up.
    Stepien KM; Hendriksz CJ
    Mol Genet Metab Rep; 2017 Dec; 13():3-6. PubMed ID: 28736719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.
    Hopkin RJ; Cabrera G; Charrow J; Lemay R; Martins AM; Mauer M; Ortiz A; Patel MR; Sims K; Waldek S; Warnock DG; Wilcox WR
    Mol Genet Metab; 2016 Sep; 119(1-2):151-9. PubMed ID: 27510433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain.
    Rombach SM; Smid BE; Bouwman MG; Linthorst GE; Dijkgraaf MG; Hollak CE
    Orphanet J Rare Dis; 2013 Mar; 8():47. PubMed ID: 23531228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic changes of lipid profile in Romanian patients with Gaucher disease type 1 under enzyme replacement therapy: a prospective study.
    Zimmermann A; Grigorescu-Sido P; Rossmann H; Lackner KJ; Drugan C; Al Khzouz C; Bucerzan S; Naşcu I; Zimmermann T; Leucuţa D; Weber MM
    J Inherit Metab Dis; 2013 May; 36(3):555-63. PubMed ID: 22976766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlations Between Serum Cholesterol and Vascular Lesions in Fabry Disease Patients.
    Katsuta H; Tsuboi K; Yamamoto H; Goto H
    Circ J; 2018 Nov; 82(12):3058-3063. PubMed ID: 30282881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes.
    Kim JH; Lee BH; Hyang Cho J; Kang E; Choi JH; Kim GH; Yoo HW
    J Hum Genet; 2016 Nov; 61(11):923-929. PubMed ID: 27334365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twenty-four-month alpha-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters.
    Koskenvuo JW; Hartiala JJ; Nuutila P; Kalliokoski R; Viikari JS; Engblom E; Penttinen M; Knuuti J; Mononen I; Kantola IM
    J Inherit Metab Dis; 2008 Jun; 31(3):432-41. PubMed ID: 18509742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Renal and Cardiac Outcomes in Male Participants in the Fabry Outcome Survey Starting Agalsidase Alfa Enzyme Replacement Therapy Before and After 18 Years of Age.
    Parini R; Pintos-Morell G; Hennermann JB; Hsu TR; Karabul N; Kalampoki V; Gurevich A; Ramaswami U;
    Drug Des Devel Ther; 2020; 14():2149-2158. PubMed ID: 32581513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical profiles of female patients with Fabry disease in Latin America: A Fabry Registry analysis of natural history data from 169 patients based on enzyme replacement therapy status.
    Martins AM; Cabrera G; Molt F; Suárez-Obando F; Valdés RA; Varas C; Yang M; Politei JM
    JIMD Rep; 2019 Sep; 49(1):107-117. PubMed ID: 31497488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.
    Mignani R; Feriozzi S; Pisani A; Cioni A; Comotti C; Cossu M; Foschi A; Giudicissi A; Gotti E; Lozupone VA; Marchini F; Martinelli F; Bianco F; Panichi V; Procaccini DA; Ragazzoni E; Serra A; Soliani F; Spinelli L; Torti G; Veroux M; Cianciaruso B; Cagnoli L
    Nephrol Dial Transplant; 2008 May; 23(5):1628-35. PubMed ID: 18057066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease.
    Prabakaran T; Birn H; Bibby BM; Regeniter A; Sørensen SS; Feldt-Rasmussen U; Nielsen R; Christensen EI
    Nephrol Dial Transplant; 2014 Mar; 29(3):619-25. PubMed ID: 24215016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of renal function in patients treated with migalastat for Fabry disease.
    Bichet DG; Torra R; Wallace E; Hughes D; Giugliani R; Skuban N; Krusinska E; Feldt-Rasmussen U; Schiffmann R; Nicholls K
    Mol Genet Metab Rep; 2021 Sep; 28():100786. PubMed ID: 34401344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme replacement therapy for Fabry disease: a systematic review of available evidence.
    Schaefer RM; Tylki-Szymańska A; Hilz MJ
    Drugs; 2009 Nov; 69(16):2179-205. PubMed ID: 19852524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of patients treated through the Canadian Fabry disease initiative.
    Sirrs SM; Bichet DG; Casey R; Clarke JT; Lemoine K; Doucette S; West ML;
    Mol Genet Metab; 2014 Apr; 111(4):499-506. PubMed ID: 24534763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.
    Hughes DA; Nicholls K; Shankar SP; Sunder-Plassmann G; Koeller D; Nedd K; Vockley G; Hamazaki T; Lachmann R; Ohashi T; Olivotto I; Sakai N; Deegan P; Dimmock D; Eyskens F; Germain DP; Goker-Alpan O; Hachulla E; Jovanovic A; Lourenco CM; Narita I; Thomas M; Wilcox WR; Bichet DG; Schiffmann R; Ludington E; Viereck C; Kirk J; Yu J; Johnson F; Boudes P; Benjamin ER; Lockhart DJ; Barlow C; Skuban N; Castelli JP; Barth J; Feldt-Rasmussen U
    J Med Genet; 2017 Apr; 54(4):288-296. PubMed ID: 27834756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications.
    Weidemann F; Niemann M; Störk S; Breunig F; Beer M; Sommer C; Herrmann S; Ertl G; Wanner C
    J Intern Med; 2013 Oct; 274(4):331-41. PubMed ID: 23586858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy: a nationwide Danish cohort study.
    Madsen CV; Bundgaard H; Rasmussen ÅK; Sørensen SS; Petersen JH; Køber L; Feldt-Rasmussen U; Petri H
    Scand Cardiovasc J; 2017 Aug; 51(4):207-216. PubMed ID: 28545342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis.
    Kampmann C; Linhart A; Devereux RB; Schiffmann R
    Clin Ther; 2009 Sep; 31(9):1966-76. PubMed ID: 19843486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease - A systematic literature review by a European panel of experts.
    Spada M; Baron R; Elliott PM; Falissard B; Hilz MJ; Monserrat L; Tøndel C; Tylki-Szymańska A; Wanner C; Germain DP
    Mol Genet Metab; 2019 Mar; 126(3):212-223. PubMed ID: 29785937
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.